Pharmatalkradio

At the 2019 Patients as Partners EU meeting, Servier's Lode Dewulf presented a discussion on connecting employee-centric culture to patient-centric culture. This presentation covered the following points: • What impact can engaged employees have on positioning the company as the preferred partner for patients and other collaborators? • How can this be done? And for what purpose? • How do you engage your employees and empower them to implement patient involvement strategies? • Inspiring employees to make change? The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020. To learn more about patient centricity in drug development and R&D and the Patients as Partners EU program, visit theconferenceforum.org.

In this podcast, listen to a session from the 2019 Patients as Partners EU conference on Sanofi Eliciting Patient Experience Data During Clinical Trials to Better Understand Patient-Perceived Benefits and Disadvantages of their Drugs. Dr Aude Roborel de Climens, PRO/COA Lead at Sanofi discusses how they capture patient experiences during clinical research and the benefit of collecting direct patient feedback. More specifically, she presents how they evaluate and analyse qualitatively and quantitatively individual patient experiences of benefits and risks of drugs during clinical trials to better understand and support clinical results and help future design of patient support programs. The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK. To learn more about patient centricity in R&D and the Patients as Partners EU program, visit theconferenceforum.org.

In this podcast, hear a session presented at the 2019 Patients as Partners EU conference on the Process to Understand the Language of Patients and the Value of Health Literacy. Who is responsible for delivering the why and how of getting involved in medicines development? Pharma, regulators or advocacy groups?What practical goals can the industry set to effect change?How are we communicating the trial information to patients and care partners to help them understand and make informed decisions?How can we address the communication challenges faced by patients and care partners while navigating the systemConsiderations for language used in adverse events reporting, informed consent and clinical trial summaries Speaker: James (Jay) Duhig, PhD, Director, Patient Integration, Pharmacovigilance and Patient Safety (PPS), AbbVie   The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020 in London, UK. To learn more about the Patients as Partners EU program and patient centricity in

In this podcast, hear a case study from the 2019 Patients as Partners EU conference on UCB and Parkinson's UK Working Together to Improve a Phase 2 Trial through Patient Involvement. In 2018, UCB and Parkinson’s UK co-developed a workshop to enable the UCB research team to work together with people affected by Parkinson’s to discuss and develop a potential phase 2 clinical trial. The aim of the workshop was to better understand people’s thoughts on clinical trials and get feedback on key features of the potential trial to maximise appropriateness, acceptability and success. In this session, attendees hear a multi-stakeholder perspective on the collaboration, including: • How the workshop was co-developed • Benefits and impact of patient involvement • Key challenges and solutions during the collaboration • Practical tips for industry and patient organisation collaborations Speakers: Natasha Ratcliffe, PhD, Research Involvement Manager, Parkinson’s UK Elaine Sutcliffe, Patient Advocate Kate Trenam, UK

The pipeline of adoptive T-cell therapies and other cell based immuno-oncology programs continues to expand with a number of modifications and improvements to the first generation programs. These platforms include improved spcificty and delivery - including non-viral platforms, targeting of multiple antigens, editing constructs, and a variety of strategies to address toxicity and the tumor microenvironment. This panel of experts, moderated by Dr Gbola Amusa, Chardan and recorded at the 5th annual Immuno-Oncology 360° Summit, will consider the major technical and clinical improvements to cell based IO therapeutics that will lead to more durable therapies and the ability to treat both liquid and solid tumors. Panelists include: Dr Robert Ang, Neon TherapeuticsDr Usman "Oz" Azam, TmunityMichael Dombeck, Precision BioSciencesDr Aiman Shalabi, GSK Save the date for the 6th annual IO360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com

This panel moderated by Dr Andrew Baum, Citi and recorded at the 5th annual IO360° Summit discusses the preparation of an IPO, straight licensing with the transition to a public company and decision making on prioritization within portfolios.  Panelists include: David Epstein, Flagship PioneeringDan Passeri, Cue Biopharma Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com

In this talk recorded at the 5th annual IO360° Summit, Dr Charles Link Jr, Newlink Genetics, addresses how IDO changes the T-cell balance in the tumor microenvironment. This talk addresses how: IDO creates local immunosuppression by increasing T regulatory cellsIDO often works in concert with PDL-1 mediated immunosuppressionIDO mediated T-cell immunosuppression leads to poor prognosis in melanoma Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com

In this podcast from the 2019 Immuno-Oncology 360° conference, Cello Health BioConsulting's EVP, Oncology Practice Head, Dr Jeff Bockman discusses deal-making and investments in the I-O space to see what can be learned about the expanding and shifting landscape of BioPharma and investor interest by examining who is placing what kinds of bets on which targets and modalities, at what stage and with what terms. Additional topics include: Where are the next big paradigm shifts going to be?Where is the next great target that will supersize foundational checkpoint therapy? Join us for the 6th annual IO360° conference on February 26-28, 2020 at the Crowne Plaza Times Square hotel in New York City. To learn more about the event, please visit IO360 2020.

Pharma Talk Radio producer, Valerie Bowling recently spoke with a young Alzheimer's patient, Jeff Borghoff. Jeff was officially diagnosed with Alzheimers in 2016 and is an active and patiionate patient advocate. Jeff generously shares his experience from diagnosis, to the experience of a clinical trial to his work in advocacy. Jeff will be speaking at the Patients as Partners conference on June 29-30, 2020 in Philadelphia. For more information, visit theconferenceforum.org We look forward to bringing you more podcasts featuring patient advocates and more on the topic of dementia. Resources that Jeff recommends: Alzherimer's AssociationAlzheimer's Congressional TeamAlzheimer's Association Early-Stage Advisory Group

In this podcast from the 2018 Mobile in Clinical Trials conference, Mohammad Ali, Global Head Digital Trials- Global Clinical Operations, Boehringer-Ingelhiem and Joe Dustin, Principal, Mobile Health, Medidata Solutions discussed the internal infrastructure that is required for the successful scaling of mobile/digital tools in clinical trials. The discussion focuses on how to come to terms with the demand of data, understanding the skill set required to purposefully use the data and implementing an internal system to allow for efficient scaling of mobile trials.? Mohammad Ali is returning to Mobile 2019 to lead an interactive group activity on creating a pathway for brainstorming the digital biomarker process. Speakers: Mohammad Ali, Global Head Digital Trials- Global Clinical Operations, Boehringer-Ingelhiem                   Joe Dustin, Principal, Mobile Health, Medidata Solutions                  

In this podcast from the 2018 Mobile in Clinical Trials conference, patient advocate, Cindy Geoghegan sat down with Dr Daniel Karlin, CEO, Healthmode and Deanna Lennon, Director of Business Development, Medable Inc for a discussion on aligning the promise of technology with the patient voice. The panel explores patient perspective on being monitored continuously and pharma perceptions of what patients want versus what patients really want. Speakers: Cindy Geoghegan, Patient Advocate                   Daniel Karlin, MD, CEO, Healthmode                   Deanna Lennon, Director of Business Development, Medable Inc                 

In this podcast from the 2018 PODD: Partnership Opportunities in Drug Delivery conference, Dr Christopher Kovalchick, Chief Engineer, Drug Delivery & Devices R&D Innovation at Eli Lilly and Company presented on incorporating of digital monitoring biomarkers into drug delivery. More specifically a framework is presented which stratifies key components and advances the concept of contextualized biomarkers. The framework codifies how direct, indirect, composite and contextualized composite data can drive innovation for the application of digital biomarkers in healthcare. In addition, application in disease and wellness is highlighted and incorporation in clinical feedback loops and closed-loop systems is illustrated.  Dr Kovalchick is returning to PODD 2019 to present on Achieving the Ultimate Outcome for Patients- Utilizing Digital Health Data to Improve Disease Management, Prevention and Overall Wellness. The 9th annual PODD conference with take place October 7-8, 2019 in Boston, MA. Learn more at t

In this podcast, Valerie Bowling, Director of PODD, walks you through what to expect at PODD 2019 in under 4 minutes. The 9th annual PODD conference features the following: Building a Company around a Transformative Drug Delivery Invention with MIT's Dr Robert Langer, Dr Sangeeta Bhati, Dr Giovanni Traverso and Harvard Medical School's Dr Jeffrey Karp.Modality Fluid Development: Tales of Evolving Pipelines and Drug Delivery Solutions with Merck's, VP, Pharmaceutical Sciences, Dr Allen TempletonGene Therapy Keynote with Spark Therapeutics, President and Head of R&D, Dr Katherine HighZeitgeist Presentation on Immune Targeting Nanomedicine by AstraZeneca’s, VP, External Innovation and Novel Product Technologies, Dr Anand SubramonyConference Chair opening remarks provided by AstraZeneca's, Dr Shawn Davis Additional Featured Speakers: Roche’s, Senior Portfolio Strategy Director, Dr Beate Bittner will moderate the Formulation & Device Lifecycle Management for Biotherapeutics – Clinical and Industry Perspect

It is estimated that between 7-10 million people, globally have Parkinson's disease.  Our guest on Pharma Talk Radio, Lesley Gosden is living with Parkinsons and she is an outstanding patient advocate, who experienced the GDNF clinical trial. In this podcast discussion, our guest will give us an insight into living with Parkinson's, about the GDNF clinical trial, lessons for all stakeholders and in particular how the success rate of clinical trials could be improved from the patient’s point of view.  Ms Gosden will be the Keynote patient advocate speaker at the Patients as Partners EU conference taking place in London on January 27th and 28th and for more information, visit theconferenceforum.org.  Guest: Lesley Gosden, Patient Advocate Host: Valerie Bowling, Producer, Pharma Talk Radio For more information about the GDNF Trial: Reflections on the GDNF Trial  

In this podcast from the 2018 Mobile in Clinical Trials conference, Dr Paul Glimcher, Julius Silver Professor of Neural Science and Physiology at NYU alongside Dr Daniel Karlin, CEO at Healthmode presented on the future of mobile data in clinical trials. Drs Glimcher and Karlin discussed this rapidly evolving space with an emphasis on the barriers and opportunities in the mobile health arena. More specifically: • What are the Barriers to gathering an incorporating Mobile data into clinical trials? • What are the most important new datatypes that are evolving in the Mobile Health space? • How can we use Real World Measurements to identify new classes of clinically relevant endpoints to go beyond Billing Codes? • Can we expect to see large-scale Mobile databases for synthetic use on the model of EMRs and ICD codes? • How should we think of these new classes of data, are they just novel bioindicators or something else? Dr Karlin is returning to Mobile 2019 as co-chair. Speakers: Paul Glimcher, PhD, Juliu

In this podcast from the 2018 Mobile in Clinical Trials conference, Eli Lilly's Joseph Kim, Sr Advisor, Clinical Operations and Digital Registry, Digital Health Office | Translational Technology & Innovation, reported on incorporating a variety of mobile devices – including a smart phone, smart insulin pens, connected devices, mifi, and laptops, into a clinical trial. Considerations and lessons learned for: • Connecting all the devices • Implementation differences between traditional vs siteless • Coordinating the equipment; challenges and successes • Lessons learned • What’s next? Speaker: Joseph Kim, Sr Advisor, Clinical Operations and Digital Registry, Digital Health Office | Translational Technology & Innovation, Eli Lilly & Co

In this podcast from Mobile in Clinical Trials 2018, Pfizer's Project Team Lead, Early Clinical Development, Digital Medicine, Dr Carrie Northcott speaks about considerations and lessons learned from the validation, verification and use of digital wearable technology in a Atopic Dermatitis Clinical Trial and some of Pfizer's forward-leaning work in decision making around novel digital endpoints.  Dr Northcott is coming back to Mobile 2019 to share results and next steps on this trial.  Speakers: Carrie Northcott, PhD, Project Team Lead, Early Clinical Development, Digital Medicine, Pfizer, Inc  

In this session presented at the Mobile in Clinical Trials 2018 conference, Merck's Kai Bode and Jyoti Shah share an exciting update on the company's progress in implementing a digital health and AI strategy. Session takeaways include: What Merck is doing in digital health and AIExternal collaborations on AISmart trial initiative to enable patient-centric studies Kai Bode is returning to Mobile 2019 to share an update on Merck's digital strategy 2.0 and how they are engineering for scale. Speakers: Jyoti Shah, Associate Director, Data Development MRL IT, Merck & Co, Inc                    Kai Bode, Director, Digital and Analytics Technology, Merck & Co, Inc

In this session from DPharm 2018, Roche provides an update on the company's progress in how they are collecting data with sensor technology and turning it into a clinically meaningful endpoint with multiple indications, including Parkinson's disease and Multiple Sclerosis. Session takeaways include: Understand what Digital Biomarker innovation means for the future of clinical development and potentially personalized healthcare.Be inspired to use mobile sensors technology in the context of clinical trials and beyond.Develop a detailed understanding of the underlying complexity to run such efforts and be able to plan for it.Understand how regulators are looking at these novel approaches. Speaker: Christian Gossens, PhD, MBA, Global Head Early Development Workflows, pRED, Informatics, Roche Pharmaceutical Research and Early Development (pRED) The 9th annual DPharm conference with take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.

This is a keynote session from DPharm 2018. Dr Atala, a renowned key opinion leader on the topic of regenerative medicine, brings the DPharm audience a fascinating presentation on how it's possible to reduce the number of patients needed in clinical trials with the advancement of regenerative medicine, and how regenerative medicine can improve accuracy and speed up the clinical trial process. Speaker: Anthony Atala, MD, Director, Wake Forest Institute for Regenerative Medicine The 9th annual DPharm conference will take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.